Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus Target Price from Analysts

Precigen, Inc. (NASDAQ:PGEN - Get Free Report) has received an average recommendation of "Moderate Buy" from the five analysts that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $7.00.

A number of research firms have commented on PGEN. JMP Securities reduced their target price on Precigen from $14.00 to $7.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 15th. HC Wainwright lowered their target price on shares of Precigen from $6.00 to $4.00 and set a "buy" rating for the company in a research note on Thursday, August 15th. Finally, StockNews.com upgraded Precigen to a "sell" rating in a report on Thursday, August 1st.

Insider Transactions at Precigen

In other news, SVP Jeffrey Thomas Perez bought 58,823 shares of the firm's stock in a transaction that occurred on Friday, August 9th. The stock was purchased at an average cost of $0.85 per share, with a total value of $49,999.55. Following the transaction, the senior vice president now directly owns 743,097 shares in the company, valued at $631,632.45. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 44.90% of the company's stock.

Institutional Trading of Precigen

Large investors have recently bought and sold shares of the business. Iridian Asset Management LLC CT raised its holdings in shares of Precigen by 82.5% in the third quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company's stock valued at $3,576,000 after buying an additional 1,706,815 shares during the last quarter. Cetera Advisors LLC acquired a new position in Precigen in the 1st quarter valued at about $367,000. Renaissance Technologies LLC raised its stake in Precigen by 12.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company's stock valued at $1,869,000 after acquiring an additional 130,500 shares during the last quarter. Mill Creek Capital Advisors LLC purchased a new stake in Precigen during the 3rd quarter valued at approximately $104,000. Finally, LexAurum Advisors LLC lifted its position in Precigen by 13.8% during the 3rd quarter. LexAurum Advisors LLC now owns 274,489 shares of the biotechnology company's stock worth $260,000 after acquiring an additional 33,300 shares during the period. Institutional investors and hedge funds own 33.51% of the company's stock.

Precigen Stock Performance

Shares of PGEN stock traded up $0.07 on Wednesday, hitting $0.90. 1,109,053 shares of the stock traded hands, compared to its average volume of 950,774. Precigen has a twelve month low of $0.79 and a twelve month high of $1.93. The firm's 50-day moving average price is $0.94 and its two-hundred day moving average price is $1.27. The stock has a market capitalization of $226.25 million, a PE ratio of -1.52 and a beta of 1.68.

Precigen (NASDAQ:PGEN - Get Free Report) last posted its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The firm had revenue of $0.72 million during the quarter, compared to analyst estimates of $1.28 million. Precigen had a negative net margin of 3,084.55% and a negative return on equity of 90.99%. On average, equities research analysts anticipate that Precigen will post -0.44 EPS for the current fiscal year.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.